Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.
Davies
D Mark
DM
Johnson
Simon R
SR
Tattersfield
Anne E
AE
Kingswood
J Chris
JC
Cox
Jane A
JA
McCartney
Deborah L
DL
Doyle
Tim
T
Elmslie
Frances
F
Saggar
Anand
A
de Vries
Petrus J
PJ
Sampson
Julian R
JR
D018207:Angiomyolipoma / Q000188:drug therapy* / Q000209:etiology; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology; D018192:Lymphangioleiomyomatosis / Q000150:complications*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011494:Protein Kinases / Q000378:metabolism; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases; D014402:Tuberous Sclerosis / Q000150:complications*
D007166:Immunosuppressive Agents; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus